Cara Therapeutics (NASDAQ:CARA) had its price target boosted by analysts at Cantor Fitzgerald from $29.00 to $33.00 in a research report issued on Wednesday, The Fly reports. Cantor Fitzgerald’s price objective indicates a potential upside of 92.98% from the company’s previous close.
A number of other equities research analysts have also recently weighed in on CARA. Zacks Investment Research cut shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 8th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Cara Therapeutics in a report on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $35.00 target price on shares of Cara Therapeutics in a research report on Tuesday. BidaskClub raised shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Finally, ValuEngine raised shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Cara Therapeutics presently has a consensus rating of “Buy” and an average price target of $27.54.
Shares of NASDAQ:CARA traded up $0.16 during trading on Wednesday, hitting $17.10. The company’s stock had a trading volume of 138,564 shares, compared to its average volume of 472,985. The business has a 50 day moving average price of $21.49 and a two-hundred day moving average price of $21.62. The company has a market capitalization of $1.04 billion, a PE ratio of -8.29 and a beta of 2.30. Cara Therapeutics has a fifty-two week low of $12.19 and a fifty-two week high of $27.55. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.21 and a current ratio of 4.21.
Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.15). The business had revenue of $5.79 million for the quarter, compared to analyst estimates of $5.56 million. Cara Therapeutics had a negative return on equity of 70.35% and a negative net margin of 470.70%. As a group, equities analysts expect that Cara Therapeutics will post -2.55 earnings per share for the current fiscal year.
In other news, Director Jeffrey L. Ives sold 2,500 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $18.21, for a total value of $45,525.00. Following the completion of the sale, the director now owns 8,500 shares of the company’s stock, valued at approximately $154,785. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Derek T. Chalmers sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $18.28, for a total value of $182,800.00. Following the completion of the sale, the chief executive officer now owns 933,468 shares of the company’s stock, valued at approximately $17,063,795.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,000 shares of company stock valued at $692,495. Corporate insiders own 5.80% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC grew its position in Cara Therapeutics by 5.9% in the second quarter. Commonwealth Equity Services LLC now owns 14,557 shares of the biopharmaceutical company’s stock worth $312,000 after acquiring an additional 814 shares in the last quarter. Creative Planning acquired a new stake in Cara Therapeutics in the second quarter worth about $207,000. SG Americas Securities LLC grew its holdings in shares of Cara Therapeutics by 46.7% during the second quarter. SG Americas Securities LLC now owns 28,760 shares of the biopharmaceutical company’s stock valued at $618,000 after buying an additional 9,161 shares during the last quarter. Aperio Group LLC acquired a new position in Cara Therapeutics in the 2nd quarter worth approximately $88,000. Finally, DekaBank Deutsche Girozentrale boosted its stake in shares of Cara Therapeutics by 340.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 59,500 shares of the biopharmaceutical company’s stock worth $1,258,000 after buying an additional 46,000 shares during the last quarter. 76.08% of the stock is currently owned by institutional investors and hedge funds.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Featured Article: Put Option
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.